BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.

Rhea-AI Summary

BioVaxys Technology Corp. completes the acquisition of IMV Inc.'s assets, expanding its portfolio in oncology, infectious disease, allergy desensitization, and autoimmune diseases. The acquisition includes clinical-stage programs like Maveropepimut-S, with plans for organic growth through licensing and partnership opportunities. The Company aims to leverage the DPX™ and HapTenix© platforms for targeted immunotherapies.

Financial Analyst

The acquisition of IMV's portfolio by BioVaxys Technology Corp. represents a strategic expansion in the biotechnology sector, focusing on oncology, infectious disease, allergy desensitization and autoimmune diseases. The one-time payment structure, combining cash and equity, is indicative of a calculated investment designed to bolster BioVaxys' assets without overleveraging its financial position. This transaction impacts the company's market valuation, as the issuance of common shares at a deemed price affects the existing shareholders' equity. The long-term value, however, hinges on the successful integration and advancement of the clinical-stage programs.

Investors should monitor the company's expenditure on these programs, as clinical development can be capital-intensive. The mention of potential licensing and partnership opportunities suggests a proactive approach to monetizing the newly acquired assets, which may lead to increased revenue streams. However, the inherent risks of clinical trials and the regulatory landscape must be factored into any financial forecasts.

The market's response to this acquisition will likely be tied to the perceived value of the DPX™ and HapTenix© platforms, as well as the progress of the clinical programs. BioVaxys' ability to communicate the benefits and potential of its expanded portfolio to investors will be crucial in maintaining and possibly enhancing investor confidence.

Medical Research Analyst

The acquisition of IMV's intellectual property by BioVaxys provides a significant boost to the company's pipeline, particularly with the addition of Maveropepimut-S to its oncology portfolio. The potential of the DPX™ platform in creating improved mRNA vaccines and multivalent viral vaccines aligns with current trends in personalized medicine and could position BioVaxys favorably in a competitive market.

From a medical research perspective, the DPX™ technology's ability to elicit a superior immune response is noteworthy. This could have implications for the efficacy of vaccines and immunotherapies, potentially leading to better patient outcomes. However, clinical success is not guaranteed and the research community will be keenly observing the progression of these assets through clinical trials.

It is also important to consider the scalability of the technology and the regulatory hurdles that come with bringing new medical treatments to market. The success of these assets will depend not only on their clinical efficacy but also on their ability to meet stringent safety standards and gain approval from health authorities.

Market Research Analyst

The strategic acquisition of IMV's assets by BioVaxys positions the company to potentially capture a larger share of the biotech market. The focus on DPX™ and HapTenix© platforms suggests a commitment to innovation in immunotherapy, a field that has seen significant investor interest. The platforms' applications in mRNA vaccines and immune system diseases are particularly relevant given the recent global emphasis on vaccine development and immunological research.

Market trends indicate a growing demand for targeted immunotherapies and personalized medicine, which could make BioVaxys an attractive partner for larger pharmaceutical companies seeking to expand their portfolios. The company's plan to identify target partners for licensing and partnership opportunities indicates a forward-thinking approach to growth and revenue diversification.

The potential for organic growth through these partnerships may drive investor optimism, but it is essential to analyze the competitive landscape and the unique value proposition BioVaxys offers. The success of these collaborations will be a key determinant of the company's market position and its ability to deliver on the promises of its expanded portfolio.

VANCOUVER, BC, Feb. 21, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce has completed the acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets of former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA ("IMV").   On February 11^th, 2024, the Company executed the definitive Asset Purchase Agreement for the extensive technology portfolio from HIMV, LLC, an acquisition vehicle formed by Horizon Technology Finance Corporation (NASDAQ: HRZN) and IMV's other secured creditors for the purpose of acquiring IMV's intellectual property through a secured party credit bid in the proceedings commenced in Canada by IMV under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the "CCAA").   

At the closing, BioVaxys delivered to HIMV a one-time payment of both US$750,000 in cash and 5,034,701 common shares of BioVaxys at a deemed price of CAD$0.067.

With the transaction now complete, BioVaxys is working on integrating the acquired assets into the Company.  BioVaxys President and Chief Operating Officer Kenneth Kovan stated "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases. Adding several clinical-stage programs was critical for us becoming a product-centric company, but there are always inherent risks with clinical programs, and they require significant investment. Maveropepimut-S has incredible potential and is a very important addition to our oncology pipeline."  Kovan further stated "Over the upcoming months our plan is to drive more organic growth by pursuing multiple licensing and partnership opportunities with the DPX™ and HapTenix© platforms. We will be identifying target partners where our solutions can address specific needs or gaps, making BioVaxys an attractive 'go-to' partner for targeted immunotherapies."

The Company has identified potential for DPX™ in improved mRNA vaccines, multivalent viral vaccines, vaccines for desensitizing immune response for peanut allergies, and immune system diseases.  Prior clinical studies by IMV have supported proof of concept and a superior immune response with a DPX™-RSV formulation, DPX™-rHA/DPX-FLU influenza vaccine, DPX™-packaged survivin/MAGE-Ag for advanced metastatic bladder cancer, and certain other infectious diseases.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).

Contact:
James Passin, CEO
+1 646 452 7054

Logo - https://mma.prnewswire.com/media/1436186/4554152/BIOVAXYS_Corporate_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/biovaxys-completes-the-acquisition-of-all-intellectual-property-immunotherapeutics-platform-technology-and-clinical-stage-assets-of-the-former-imv-inc-302067847.html

SOURCE BioVaxys Technology Corp.

What assets did BioVaxys Technology Corp. acquire?

BioVaxys Technology Corp. acquired the entire portfolio of discovery, preclinical, and clinical development stage assets of IMV Inc., Immunovaccine Technologies Inc., and IMV USA.

What was the payment made by BioVaxys in the acquisition?

BioVaxys made a one-time payment of US$750,000 in cash and 5,034,701 common shares of BioVaxys at a deemed price of CAD$0.067.

What opportunities does BioVaxys have after the acquisition?

BioVaxys now has opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases, with a focus on integrating the acquired assets into the Company.

What is the potential of DPX™ according to BioVaxys?

BioVaxys sees potential for DPX™ in improved mRNA vaccines, multivalent viral vaccines, vaccines for desensitizing immune response for peanut allergies, and immune system diseases based on prior clinical studies by IMV.

What is BioVaxys' plan for organic growth post-acquisition?

BioVaxys plans to drive more organic growth by pursuing multiple licensing and partnership opportunities with the DPX™ and HapTenix© platforms, aiming to become an attractive partner for targeted immunotherapies.